Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ).
Jiangsu Recbio Technology Co., Ltd. announced the completion of the issuance of 143,112,702 fully paid Domestic Shares, increasing its total issued shares to 626,075,702. This issuance significantly altered its shareholding structure, granting Yangtze River Pharmaceutical a substantial stake and shifting the overall percentage of Domestic and H Shares, which could impact its market positioning and investor dynamics.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a biotechnology company incorporated in China that specializes in vaccine research and development. It focuses on innovative immunization solutions and is listed on the Hong Kong Stock Exchange with a notable presence in the biopharmaceutical industry.
Average Trading Volume: 40,055
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.63B
For an in-depth examination of 2179 stock, go to TipRanks’ Overview page.